Physician profile
Norman C Smith
NPI 1184776049
$3,489.76
in general payments reported to CMS, 2019-2025
23 companies · $1,225 in 2025
The $1,225 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $182 · 2020: $450 · 2021: $520 · 2022: $299 · 2023: $318 · 2024: $495 · 2025: $1,225.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,038.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,038.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,035.83 | 2019-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $539.97 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Lilly USA, LLC | $525.06 | 2019-2025 | Zepbound, Mounjaro |
| Abbvie INC. | $234.92 | 2019-2025 | Ubrelvy, Qulipta |
| Corcept Therapeutics | $216.81 | 2025 | Korlym |
| Abbott Laboratories | $180.08 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Pfizer INC. | $108.73 | 2020-2025 | |
| Kowa Pharmaceuticals America, INC. | $95.50 | 2020-2025 | Zoryve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $90.65 | 2020-2025 | Jardiance |
| Exact Sciences Corporation | $85.14 | 2023-2025 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $77.31 | 2019-2022 | |
| Medtronic, INC. | $46.71 | 2024 | Endurant Iis, Closurefast |
| Merck Sharp & Dohme LLC | $39.69 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $37.67 | 2020 | |
| Horizon Therapeutics Plc | $30.96 | 2019-2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $24.10 | 2020 | |
| Genentech USA, INC. | $19.97 | 2021 | |
| Amgen INC. | $19.83 | 2025 | Repatha |
| Biohaven Pharmaceutical Holding Company LTD. | $18.99 | 2022 | |
| Paratek Pharmaceuticals, INC. | $17.75 | 2025 | Nuzyra |
| Biohaven Pharmaceuticals, INC. | $17.50 | 2021 | |
| Glaxosmithkline, LLC. | $15.48 | 2023 | Arexvy, Shingrix |
| Metuchen Pharmaceuticals | $11.11 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Norman Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.